Skip to content

Photoacoustic Imaging (PAI) of Suspicious Breast Cancers - A Clinical Feasibility Study

Pilot Photoacoustic Imaging (PAI) of Suspicious Breast Cancers - A Clinical Feasibility Study

Status
Withdrawn
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01780532
Enrollment
0
Registered
2013-01-31
Start date
2014-09-30
Completion date
2016-03-31
Last updated
2017-01-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Brief summary

After locating the suspicious lesion/mass with standard of care mammography and/or ultrasound, a photoacoustic scan will be performed in the breast where the lesion is located. After the PA scan a biopsy will be performed, if clinically indicated (based on the mammogram and ultrasound only).

Interventions

PROCEDUREPhotoacoustic Imaging (PAI)

Standard of Care

Sponsors

Stanford University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Patients must have a breast lesion/mass found at physical examination, mammography or ultrasound (US), that has not been surgically resected * Patients may have any of the following characteristics: * Taking hormones (e.g., contraceptives, hormone replacement therapy, post-cancer Tamoxifen) * Breast implants * Previous breast biopsy * Previous breast surgery * Previous breast cancer * High risk of breast cancer (e.g., breast cancer susceptibility gene (BRCA) mutations, other gynecologic cancer) * Ability to understand and the willingness to sign a written informed consent document

Exclusion criteria

* Patients who have had primary surgical excision of the suspicious finding * Pregnant or lactating women

Design outcomes

Primary

MeasureTime frame
The lesion visibility on PAI, described using a five-level scale: 1. Not visible 2. Barely visible 3. Fair (or moderately visible) 4. Visible 5. Clearly visible.6 months

Secondary

MeasureTime frame
Measures of hypoxia in the lesion6 months

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026